Back to search
FDAFDA · Food and drugs·Recall number D-0055-2018

Duloxetine Delayed-release Capsules USP, 20 mg, 50 Capsules (5 x 10) Unit Dose per carton, unit dose blister UPC 5026828311), Rx only, Manufactured for: AvKARE, Inc., Pulaski, TN 38478, NDC 50268-283-15.

Published November 8, 2017 · Recall initiated: October 6, 2017

Summary

FDA records drug Class II recall D-0055-2018, published November 8, 2017 and initiated October 6, 2017. Recalling firm: AVKARE Inc.; Status: Terminated; Reported quantity: 274 cartons; Lot: Lot: 18103 Exp. 11/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: slightly elevated levels of phthalic acid.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AVKARE Inc.
Distributor
Nationwide in the USA
Lot
Lot: 18103 Exp. 11/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-release Capsules USP, 20 mg, 50 Capsules (5 x 10) Unit Dose per carton, unit dose blister UPC 5026828311), Rx only, Manufactured for: AvKARE, Inc., Pulaski, TN 38478, NDC 50268-283-15. recalled?

Yes. FDA published recall D-0055-2018 on November 8, 2017. Reported hazard: Failed Impurities/Degradation Specifications: slightly elevated levels of phthalic acid.

What should I do if I have this product?

Voluntary: Firm initiated · Letter